Stock Track | BeiGene Soars 7.74% as Strong Revenue Growth Fuels Optimism

Stock Track

Feb 28, 2025

BeiGene Ltd's (6160) shares surged 7.74% in the intraday trading session on Friday, riding on the crest of robust revenue growth and a promising outlook for the oncology treatments developer.

The Hong Kong-listed stock hit a three-year high of HK$174.8, reflecting investors' enthusiasm for the company's stellar performance. BeiGene reported a remarkable 78% year-over-year increase in total global revenues to $1.1 billion for the fourth quarter of 2024 and a 55% year-over-year increase to $3.8 billion for the full year.

Adding to the optimism, the company provided full-year 2025 revenue guidance of $4.9 billion to $5.3 billion, underscoring its confidence in sustained growth. Nomura analysts, who have a "Buy" rating on the stock, praised the Q4 2024 sales beat, attributing it to balanced growth across the US, China, and EU markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1168390449"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168390449\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168390449?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168390449","market":"hk","top_or_hot":-1,"title":"Stock Track | BeiGene Soars 7.74% as Strong Revenue Growth Fuels Optimism","media":"Stock Track","content":"<p>BeiGene Ltd's (6160) shares surged 7.74% in the intraday trading session on Friday, riding on the crest of robust revenue growth and a promising outlook for the oncology treatments developer.</p>\n\n<p>The Hong Kong-listed stock hit a three-year high of HK$174.8, reflecting investors' enthusiasm for the company's stellar performance. BeiGene reported a remarkable 78% year-over-year increase in total global revenues to $1.1 billion for the fourth quarter of 2024 and a 55% year-over-year increase to $3.8 billion for the full year.</p>\n\n<p>Adding to the optimism, the company provided full-year 2025 revenue guidance of $4.9 billion to $5.3 billion, underscoring its confidence in sustained growth. Nomura analysts, who have a \"Buy\" rating on the stock, praised the Q4 2024 sales beat, attributing it to balanced growth across the US, China, and EU markets.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeiGene Soars 7.74% as Strong Revenue Growth Fuels Optimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeiGene Soars 7.74% as Strong Revenue Growth Fuels Optimism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 10:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeiGene Ltd's (6160) shares surged 7.74% in the intraday trading session on Friday, riding on the crest of robust revenue growth and a promising outlook for the oncology treatments developer.</p>\n\n<p>The Hong Kong-listed stock hit a three-year high of HK$174.8, reflecting investors' enthusiasm for the company's stellar performance. BeiGene reported a remarkable 78% year-over-year increase in total global revenues to $1.1 billion for the fourth quarter of 2024 and a 55% year-over-year increase to $3.8 billion for the full year.</p>\n\n<p>Adding to the optimism, the company provided full-year 2025 revenue guidance of $4.9 billion to $5.3 billion, underscoring its confidence in sustained growth. Nomura analysts, who have a \"Buy\" rating on the stock, praised the Q4 2024 sales beat, attributing it to balanced growth across the US, China, and EU markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1168390449","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168390449","pubTimestamp":1740708654,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BeiGene Ltd's  shares surged 7.74% in the intraday trading session on Friday, riding on the crest of robust revenue growth and a promising outlook for the oncology treatments developer.The Hong Kong-listed stock hit a three-year high of HK$174.8, reflecting investors' enthusiasm for the company's stellar performance. BeiGene reported a remarkable 78% year-over-year increase in total global revenues to $1.1 billion for the fourth quarter of 2024 and a 55% year-over-year increase to $3.8 billion f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"由于强劲的收入增长激发乐观情绪，百济神州股价飙升7.74%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"BeiGene Ltd's (6160) shares surged 7.74% in the intraday trading session on Friday, riding on the crest of robust revenue growth and a promising outlook for the oncology treatments developer.\nThe Hong Kong-listed stock hit a three-year high of HK$174.8, reflecting investors' enthusiasm for the company's stellar performance. BeiGene reported a remarkable 78% year-over-year increase in total global revenues to $1.1 billion for the fourth quarter of 2024 and a 55% year-over-year increase to $3.8 billion for the full year.\nAdding to the optimism, the company provided full-year 2025 revenue guidance of $4.9 billion to $5.3 billion, underscoring its confidence in sustained growth. Nomura analysts, who have a \"Buy\" rating on the stock, praised the Q4 2024 sales beat, attributing it to balanced growth across the US, China, and EU markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}